Background. Risk factors for invasive fusariosis (IF) have not been characterized. We attempted to identify risk factors for IF in a prospective cohort of hematologic patients treated in 8 centers in Brazil.
Invasive fungal disease (IFD) represents a major complication in patients with acute myeloid leukemia (AML) and in hematopoietic cell transplant (HCT) recipients [1, 2] . Whereas invasive aspergillosis is the most frequent IFD in such patients, infections caused by other molds have been increasingly reported [3] . Invasive fusariosis is one of these emerging invasive mold disease (IMD), being the second or third most frequent IFD in HCT recipients [4, 5] .
Clinical features and prognostic factors of invasive fusariosis have been well characterized [6] [7] [8] , but very little is known about risk factors. Studies describing risk factors for IMD have been published, but the overwhelming majority of cases were due to Aspergillus species [9, 10] . Although similar to aspergillosis in many aspects, invasive fusariosis has unique features, including a cutaneous portal of entry in some cases, and the production of yeast-like structures (aleuroconidia) by Fusarium species, resulting in a clinical picture characterized by the appearance of metastatic skin lesions and positive blood cultures [6, 9, 11] .
We have recently reported a high incidence of invasive fusariosis in patients with AML or myelodysplasia (MDS) undergoing induction remission chemotherapy and in HCT recipients in Brazil [12] . In this study, we attempted to identify risk factors for invasive fusariosis occurring in patients from this prospective cohort.
PATIENTS AND METHODS
A prospective cohort study was conducted in 8 centers located in 7 cities in the south and southeast of Brazil. All centers are tertiary care hospitals, with active programs of hematology and HCT, and the study was approved by the institutional review board of each participating center. From May 2007 to July 2009, all HCT recipients (autologous or allogeneic) and all patients with a recent diagnosis of AML or MDS undergoing induction remission chemotherapy were followed prospectively for 1 year (HCT recipients) or until the end of the last cycle of consolidation chemotherapy (AML/MDS). All centers had high-resolution computed tomography and automated blood culture systems, and the patients were followed by clinicians familiar with criteria and tools for the diagnosis of IFD, including invasive fusariosis.
We collected baseline characteristics from all patients in the cohort including demographic information (age, sex), active smoking history, underlying disease and its status and treatment, type and characteristics of HCT (autologous vs allogeneic, stem cell source, human leukocyte antigen matching, conditioning regimen), cytomegalovirus (CMV) serostatus of recipient and donor, CMV reactivation, presence of graft-vshost disease (GVHD) and its treatment, antifungal prophylaxis, comorbidities, duration of neutropenia, and prior IFD. If the patient developed an IFD, detailed information of the diagnosis and treatment was collected.
The cases of invasive fusariosis were blindly reviewed by a data review committee, and classified as proven or probable, according to the modified European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria [13] . Cases of possible fusariosis were excluded.
Patients were managed according to the routine of each center. Neutropenia was defined as an absolute neutrophil count <0.5 cells/µL. Mold-active antifungal prophylaxis was defined when the patient received prophylaxis with voriconazole or posaconazole. The date of the diagnosis of IFD was defined as the date of the first clinical documentation of infection (signs, symptoms, and radiologic and other findings that were interpreted by the clinician as representing an IFD). If the diagnosis was obtained postmortem, the date of death was recorded as the date of diagnosis of IFD.
For the assessment of risk factors for invasive fusariosis, we compared patients with (cases) and without (controls) a diagnosis of invasive fusariosis. Two analyses were performed, one in patients with AML/MDS and other in allogeneic HCT recipients. In the HCT cohort, we arbitrarily classified invasive fusariosis according to the time of diagnosis related to the date of HCT as early (until day 40) and late (after day 40). Risk factors for invasive fusariosis were assessed using univariate Cox regression analysis. All tests were 2-tailed and P values <.05 were considered statistically significant. Statistical analysis was performed using SPSS 15.0 software (SPSS Inc, Chicago, Illinois).
RESULTS
During the study period, we analyzed 900 episodes: 237 induction remission courses of AML/MDS in 218 patients, and 663 HCTs (345 allogeneic and 318 autologous) in 650 patients. The median age of the 868 patients was 38 years (range, 0-82), and 56% were males. A total of 25 cases of invasive fusariosis were diagnosed. The distribution of cases in the 8 centers is shown in Table 1 . The incidence of invasive fusariosis was higher in 1 center. The clinical characteristics of these cases did not differ from cases occurring in other centers. The cases in this center were spread throughout the study period, and no seasonal pattern was observed.
Invasive Fusariosis in AML/MDS
Among the 237 induction remission courses of AML/MDS, 183 (77.2%) were AML in the first induction remission, 47 (19.8%) were AML in relapse, and 7 (3%) were MDS. Eight cases of invasive fusariosis were diagnosed (3.4%): 7 in AML patients during the first induction remission, and 1 in a relapsed patient. The median time from the start of chemotherapy to the diagnosis of invasive fusariosis was 23.5 days (range, 16-38 days), and the median duration of neutropenia before the diagnosis of invasive fusariosis was 22.5 days (range, 10-34 days). All patients were neutropenic at diagnosis of fusariosis. Fever, skin lesions, and pneumonia were the most frequent clinical manifestations ( Table 2 ). Three of the 8 patients died (37.5%).
As shown in Table 3 , the only significant variable associated with invasive fusariosis in AML patients was active smoking (hazard ratio, 9.11 [95% confidence interval, 2.04-40.71]; P = .004).
Invasive Fusariosis in HCT Recipients
A total of 17 cases of invasive fusariosis were diagnosed in the 663 HCTs (2.6%): 2 in 318 autologous HCTs (0.6%), and 15 in the 345 allogeneic HCTs (4.3%). The 2 cases in autologous HCT occurred in the same hospital (center 7), in patients with multiple myeloma, on days 6 and 7 posttransplant, respectively (2 and 4 days of neutropenia before the diagnosis of fusariosis). Both patients survived.
Among the 15 cases of invasive fusariosis diagnosed in allogeneic HCT recipients, 10 were diagnosed in the early period, before day 40 (median, day 19 [range, 7-36]), with a median duration of neutropenia before the diagnosis of fusariosis of 20 days (range, 2-53). Five cases occurred after day 40 (median, day 116 [range, 50-174]). Neutropenia was present in all cases occurring before day 40 and in 1 case occurring after day 40 (P = .004). Fever was more frequent in early fusariosis ( Table 2) .
As shown in Table 4 , variables associated with invasive fusariosis occurring in the early posttransplant period (until day 40) were AML, center 7, receipt of antithymocyte globulin (ATG) in the conditioning regimen, and hyperglycemia requiring therapy with insulin. For invasive fusariosis occurring in the late posttransplant period (after day 40), significant variables were a history of IMD before HCT, nonmyeloablative conditioning regimen, and grade III/IV GVHD.
DISCUSSION
In this study, we found that smoking history was the only significant variable associated with invasive fusariosis in AML patients. In allogeneic HCT recipients, risk factors varied according to the phase of transplant: AML as underlying disease, b Duration of neutropenia until the diagnosis of invasive fusariosis in cases, and until bone marrow recovery or the last day of follow-up in controls.
hyperglycemia requiring insulin therapy, receipt of ATG, and center 7 were associated with invasive fusariosis in the early posttransplant period, whereas IMD before transplant, nonmyeloablative conditioning regimen, and grade III/IV GVHD were risk factors after day 40 posttransplant.
As recently reported by our group [12] , the incidence of invasive fusariosis in patients with AML and in HCT recipients in Brazil is very high compared with studies from other regions of the globe [4, 5, 14] . In the present study, we expanded the analysis of the epidemiology of invasive fusariosis, and attempted to identify risk factors.
To our knowledge, this is the first study evaluating risk factors for invasive fusariosis in patients with AML. Active smoking was the only significant variable. Smoking has been associated with an increased risk of cryptococcosis [15] , paracoccidioidomycosis [16] , and coccidioidomycosis [17] . In addition, a study evaluating prehospital variables as potential risk factors for IFD in patients with acute leukemia found an association between smoking and IMD by univariate but not multivariate analysis [18] . Interestingly, we have recently reported an increase in the incidence of invasive fusariosis in our center [19] , and molecular typing suggested an acquisition in the community [20] . Unfortunately, as smoking history was the only prehospital variable analyzed in the present study, we could not evaluate other potential risk factors, including variables that could directly influence the risk of IFD, such as chronic lung disease.
The mechanism by which smoking may predispose to invasive fusariosis may be related to the interference in the phagocytic function of alveolar macrophages [21] and the production of various proinflammatory cytokines [22] . Contamination of tobacco with Fusarium has been reported and could be another explanation [23] .
Risk factors for invasive fusariosis in HCT recipients were evaluated in one study. Marr et al [24] characterized the epidemiology of IMD in a large cohort of HCT recipients and identified 2 variables associated with invasive fusariosis: multiple myeloma and mismatched or unrelated transplant.
In the present study, receipt of ATG was associated with invasive fusariosis occurring in the early posttransplant period. In another study, ATG was an independent risk factor for IMD occurring in the early posttransplant period in allogeneic HCT recipients [10] . These findings suggest that in addition to neutropenia, which occurs in virtually all allogeneic HCT recipients in this phase, severe T-cell immunodeficiency is an important additional risk factor, as supported by studies that reported higher incidences of IFD in T-cell-depleted transplants [25, 26] . We found that patients with hyperglycemia requiring insulin therapy were at increased risk to develop invasive fusariosis until day 40 posttransplant. Hyperglycemia exerts various deleterious effects in the innate immune system, including impairment in neutrophil function [27] , and has been identified as a risk factor for candidemia [28] , mucormycosis [29] , and infectious complications (including IFD) in patients with acute leukemia [30, 31] .
Among the 8 participating centers, only 2 did not report a case of invasive fusariosis among allogeneic HCT recipients. The incidence in the remaining 6 centers varied widely, and was significantly higher in center 7. This center also reported the 2 cases of fusariosis in autologous HCT recipients. An increase in the incidence of invasive fusariosis was reported in this center [19] , but a nosocomial acquisition of infection was unlikely according to molecular typing of patients' and hospital environmental isolates [20] . Interestingly, most of these patients had a cutaneous portal of entry. A subsequent study from the same group showed that a substantial proportion of patients with hematologic patients at high risk to develop invasive fusariosis had skin breakdowns on admission (onychomycosis and/ or intertrigo), and when Fusarium species grew from such lesions, the risk for invasive fusariosis increased [32] . Unfortunately, in the present study, information about skin breakdowns on admission was not available.
Similar to other studies that reported an association between IMD and the underlying disease [10] , AML was associated with early fusariosis in the present study. In most such patients, leukemia was in relapse, increasing the risk for IMD.
Nonmyeloablative conditioning regimen was associated with late fusariosis. Late IFDs are frequently reported in nonmyeloablative transplants [33, 34] , and probably result from a combination of shorter duration of neutropenia in the early posttransplant period and a higher incidence of GVHD later in the course of transplant [35, 36] . Another variable associated with invasive fusariosis after day 40 posttransplant was grade III/IV GVHD. This variable is a major driver of severe immunodeficiency in this phase of transplant and has been identified as a risk factor for IFD in other studies [10, 25, [37] [38] [39] . The same is true for prior IMD [40] .
Our study has several limitations. First, we did not have details of patients' smoking habits such as the degree and duration of exposure. Second, we could not evaluate the association between smoking and fusariosis in the HCT recipients because only 5% of patients in this cohort had a history of active smoking. Third, we did not evaluate other prehospital factors that could be associated with fusariosis, including the presence of skin breakdowns at baseline. Fourth, information about CMV serostatus of recipient and donor was not available for 30 HCTs, including 6 of the 15 cases of invasive fusariosis. Fifth, despite the high incidence of invasive fusariosis in the cohort, the numbers are small, reducing the power of the analyses, including the performance of multivariate analysis. Despite these limitations, our study may have implications for clinical practice and future research. Attempts to reduce the risk of invasive fusariosis may include smoking cessation, aggressive control of hyperglycemia, and the use of a mold-active agent as prophylaxis in patients receiving ATG in the conditioning regimen or developing GVHD. In addition, future research should further explore smoking and other prehospital variables as risks for invasive fusariosis.
In conclusion, smoking history was associated with invasive fusariosis in AML patients, hyperglycemia requiring insulin therapy, receipt of ATG, AML, and center 7 were risk factors in the early posttransplant period; and nonmyeloablative conditioning regimen, previous IMD, and grade III/IV GVHD were associated with invasive fusariosis after day 40 posttransplant. The identification of these factors may help to establish a risk-based approach to prevent the occurrence of this devastating disease.
Notes

